quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 19, 2026

Zacks Industry Outlook Highlights Visa, Mastercard, Fiserv, Fidelity National Information Services and Global Payments

View original at finance.yahoo.com
Zacks Industry Outlook Highlights Visa, Mastercard, Fiserv, Fidelity National Information Services and Global Payments For Immediate Release Chicago, IL – February 19, 2026 – Today, Zacks Equity Research discusses Visa Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Financial Transaction Services industry is likely to benefit from expanding global trade, rising international travel and growing demand for seamless cross-border payments and remittances

    80% confidence
  • Solid momentum in Latin America, Canada and the United States has been a major contributor to Visa's overall growth

    80% confidence
  • The Zacks Financial Transaction Services industry currently carries a Zacks Industry Rank #135, which places it in the bottom 44% of 243 Zacks industries

    80% confidence
  • Fidelity National is delivering solid revenue growth, fueled by robust performance in its Banking Solutions and Capital Markets Solutions segments

    80% confidence
  • Technology spending is climbing as companies invest heavily in digital infrastructure, biometric authentication, QR-code payments and Buy Now, Pay Later platforms to combat rising fraud and data breaches

    80% confidence
  • Visa is a major global powerhouse in digital payments expanding its footprint through new strategic alliances, renewals of long-standing deals and acquisitions

    80% confidence
  • Mastercard Move facilitates secure and seamless international money transfers across more than 200 countries

    80% confidence
  • Global Payments is well-positioned to capitalize on future growth opportunities, driven by strong performances in its Merchant Solutions and Issuer Solutions segments

    80% confidence
  • The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one

    80% confidence
  • Mastercard operates a multi-rail infrastructure that supports card, account-to-account payments and real-time payments

    80% confidence
  • The majority of Fidelity National's revenues is derived from U.S. clients

    80% confidence
  • With expectations for interest rate cuts in 2026, companies may increasingly use debt financing to fund acquisitions and accelerate growth

    80% confidence
  • Continued e-commerce growth and a resilient labor market are sustaining transaction volumes

    80% confidence
  • Fiserv maintains a solid competitive position in the digital payments space, supported by its broad portfolio of solutions

    80% confidence
  • Persistent inflation and tariff pressures may further strain consumer budgets

    80% confidence

Data points we hold from this source

Visa Inc. · earnings beat rate4 quarters_out_of_4
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Zacks Industry Outlook Highlights Visa, Mastercard, Fiserv, Fidelity National Information Services and Global Payments — Source | Via News | pt.VIA.NEWS